News und Analysen
![Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
![Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Mit EVIS X1 bringt Olympus sein bisher modernstes Endoskopiesystem auf den Markt
Die Olympus Corporation (Präsident: Yasuo Takeuchi) hat heute die Markteinführung ihres bisher modernsten Endoskopiesystems EVIS X1 bekannt gegeben. Das neue System soll mit innovativen und
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Gilead Sciences: Einfach kein entscheidender Durchbruch!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
![Gilead Sciences: Einfach kein entscheidender Durchbruch!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
![Gilead Sciences: Einfach kein entscheidender Durchbruch!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
![LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products are now permitted to be used in the U.S. for
![Agilent Signs Sponsorship Agreement with My Green Lab](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Agilent Signs Sponsorship Agreement with My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific
![Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced its 2019 financial
![Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial
![Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets. Clovis’ senior management will
![Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO)
![NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) today announced updates to the Company’s operational and global development plan in light of the
![Premier Inc. Real-Time Technology Solution Tracks, Manages and Supports Treatment of COVID-19 Patients Across the Country](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Premier Inc. Real-Time Technology Solution Tracks, Manages and Supports Treatment of COVID-19 Patients Across the Country
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, is marshaling all its data and technology capabilities to provide real-time, integrated solutions that help make it easier for
![Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Premier Inc. Survey: Isolation Gowns Replace N95 Masks as the Top Shortage Concern Among Hospitals and Health Systems Treating COVID-19 Patients](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Premier Inc. Survey: Isolation Gowns Replace N95 Masks as the Top Shortage Concern Among Hospitals and Health Systems Treating COVID-19 Patients
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that isolation gowns surpassed N95 masks as the top personal protective equipment (PPE)
![Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will
![Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
![Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
![Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
![Evotec: Neue Knaller-Kooperation](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Evotec: Neue Knaller-Kooperation
Evotec (WKN: 566480) verkündet heute eine strategische Partnerschaft und Beteiligungsvereinbarung mit leon-nanodrugs aus München. Mit der auf Innovation ausgerichteten Zusammenarbeit will Evotec
![Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, April 30, 2020, to discuss its financial and operating